Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Phase III Study of Second-Line Chemotherapy With or Without Panitumumab for KRAS Wild Type, Locally Advanced or Metastatic Pancreatic Adenocarcinoma

NCT06998940 is registered in ClinicalTrials.gov with SWOG Cancer Research Network as lead sponsor.

NCT NCT06998940
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06998940 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Phase III Study of Second-Line Chemotherapy With or Without Panitumumab for KRAS Wild Type, Locally Advanced or Metastatic Pancreatic Adenocarcinoma
Lead sponsor
SWOG Cancer Research Network
Phase
Phase 3
Overall status
Recruiting
Start date
May 13, 2026
Completion date
December 31, 2030
Enrollment
94 (estimated)
Sites
274

Conditions

As the registry lists them; a condition with its own page is linked.

locally advanced pancreatic adenocarcinoma, metastatic pancreatic adenocarcinoma, stage iii pancreatic cancer ajcc v8, stage iv pancreatic cancer ajcc v8, unresectable pancreatic adenocarcinoma